RIMA antidepressants market seen reaching $7.49 billion by 2030

The reversible inhibitors of monoamine oxidase A antidepressants market is projected to grow from $5.67 billion in 2025 to $7.49 billion by 2030, driven by rising depression and anxiety cases, higher healthcare spending and broader precision medicine adoption. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - The market is expanding as demand rises for antidepressant options that are reversible and easier to manage than older monoamine oxidase inhibitors. - Growth in mental health treatment spending and personalized care could widen access to these therapies. - The forecast points to a larger commercial opportunity for drug developers and psychiatric care providers through 2030.

What happened: - The Business Research Company projected the reversible inhibitors of monoamine (RIMA) antidepressants market will rise from $5.67 billion in 2025 to $5.98 billion in 2026. - The report forecast the market will reach $7.49 billion by 2030. - The report said the market is growing at a 5.5% CAGR from 2025 to 2026 and a 5.8% CAGR from 2026 to 2030. - The report was released Sept. 15, 2026, in London. - A free sample of the report is available.

The details: - RIMA antidepressants selectively and temporarily inhibit monoamine oxidase A. - The drugs increase levels of serotonin, norepinephrine and dopamine in the brain. - RIMAs bind reversibly to the enzyme, which allows controlled modulation of monoamine metabolism. - The reversible binding lowers the risk of long-term enzyme inhibition and related side effects compared with older MAO inhibitors. - The report pointed to rising depression and anxiety rates worldwide as a major demand driver. - The report also cited safer and more tolerable treatment options that avoid the strict dietary restrictions linked to earlier therapies. - The American Psychiatric Association reported in May 2024 that 43% of U.S. adults felt more anxious in 2024, up from 37% in 2023 and 32% in 2022. - The report linked higher healthcare spending to broader adoption of RIMA antidepressants. - The American Medical Association said in April 2025 that U.S. healthcare spending rose 7.5% in 2023 to $4.9 trillion, or $14,570 per person, after a 4.6% increase in 2022. - The report said precision medicine is helping shape demand by tailoring treatment to genetic profiles, lifestyles and disease characteristics. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, more than double the six approvals in 2022. - Key trends in the market include personalized psychiatry, biomarker-driven treatment optimization and expanded outpatient psychiatric care models. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The forecast suggests RIMA antidepressants are benefiting from a broader shift toward precision psychiatry and outpatient mental health care. - The combination of rising anxiety levels and more healthcare funding may support steady demand even without a breakthrough therapy. - The regional split points to mature adoption in North America and faster expansion potential in Asia-Pacific.

What's next: - The market is expected to keep expanding through 2030 as telepsychiatry, digital therapeutics and biomarker-based treatment planning gain traction. - The Business Research Company said its 2026 report set includes market attractiveness scoring, TAM analysis, a company scoring matrix, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - The company also provided contact details for sales and expert outreach and linked to its company website.